Spark Therapeutics, Inc. (ONCE) Analysts See $-0.94 EPS

October 11, 2018 - By Linda Rogers

Spark Therapeutics, Inc. (NASDAQ:ONCE) LogoInvestors sentiment is 1.19 in 2018 Q2. Its the same as in 2018Q1. It is flat, as 17 investors sold Spark Therapeutics, Inc. shares while 46 reduced holdings. only 24 funds opened positions while 51 raised stakes. 37.08 million shares or 0.93% more from 36.74 million shares in 2018Q1 were reported.
Bankshares Of Ny Mellon holds 141,367 shares. Florida-based Raymond James Associate has invested 0% in Spark Therapeutics, Inc. (NASDAQ:ONCE). Metropolitan Life Insur Ny invested in 0% or 10,207 shares. State Board Of Administration Of Florida Retirement Systems has invested 0% of its portfolio in Spark Therapeutics, Inc. (NASDAQ:ONCE). New Jersey-based Prudential has invested 0% in Spark Therapeutics, Inc. (NASDAQ:ONCE). New York-based Tocqueville Asset Mgmt L P has invested 0.04% in Spark Therapeutics, Inc. (NASDAQ:ONCE). Glenmede Trust Co Na stated it has 0% of its portfolio in Spark Therapeutics, Inc. (NASDAQ:ONCE). The Minnesota-based Ameriprise Finance has invested 0% in Spark Therapeutics, Inc. (NASDAQ:ONCE). Blair William & Il owns 9,520 shares or 0.01% of their US portfolio. Tci Wealth Advsr Incorporated accumulated 6 shares or 0% of the stock. Bnp Paribas Arbitrage reported 2,242 shares stake. Morgan Stanley reported 0.01% in Spark Therapeutics, Inc. (NASDAQ:ONCE). Federated Pa owns 0.37% invested in Spark Therapeutics, Inc. (NASDAQ:ONCE) for 1.52M shares. Fmr Limited Liability reported 0.05% stake. Mackay Shields Ltd Llc reported 10,289 shares stake.

Analysts expect Spark Therapeutics, Inc. (NASDAQ:ONCE) to report $-0.94 EPS on November, 6.They anticipate $0.96 EPS change or 50.53 % from last quarter’s $-1.9 EPS. After having $2.07 EPS previously, Spark Therapeutics, Inc.’s analysts see -145.41 % EPS growth. The stock decreased 4.18% or $2.06 during the last trading session, reaching $47.28. About 400,275 shares traded. Spark Therapeutics, Inc. (NASDAQ:ONCE) has declined 28.27% since October 11, 2017 and is downtrending. It has underperformed by 43.89% the S&P500.

Spark Therapeutics, Inc. (NASDAQ:ONCE) Ratings Coverage

Among 14 analysts covering Spark Therapeutics (NASDAQ:ONCE), 5 have Buy rating, 1 Sell and 8 Hold. Therefore 36% are positive. Spark Therapeutics had 20 analyst reports since April 19, 2018 according to SRatingsIntel. As per Wednesday, August 8, the company rating was downgraded by BMO Capital Markets. As per Monday, April 23, the company rating was downgraded by Chardan Capital Markets. Cantor Fitzgerald maintained the shares of ONCE in report on Tuesday, May 22 with “Buy” rating. UBS maintained the shares of ONCE in report on Wednesday, August 8 with “Neutral” rating. Stifel Nicolaus maintained Spark Therapeutics, Inc. (NASDAQ:ONCE) on Wednesday, May 9 with “Buy” rating. As per Thursday, July 19, the company rating was downgraded by RBC Capital Markets. The firm has “Buy” rating given on Monday, April 30 by Cantor Fitzgerald. As per Monday, June 25, the company rating was maintained by BMO Capital Markets. The stock of Spark Therapeutics, Inc. (NASDAQ:ONCE) has “Overweight” rating given on Wednesday, August 8 by Barclays Capital. On Tuesday, May 1 the stock rating was maintained by Mizuho with “Buy”.

Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. The company has market cap of $1.78 billion. The Company’s products include voretigene neparvovec, which is in Phase III clinical trial for the treatment of genetic blinding conditions called inherited retinal diseases caused by non sex-linked, autosomal recessive, or biallelic mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia. It currently has negative earnings. The company's products also comprise SPK-7001 that is in Phase 1/2 trial for choroideremia; SPK-9001, which is in Phase 1/2 trial for hemophilia B; and SPK-8011 that is in Phase 1/2 trial hemophilia A.

More important recent Spark Therapeutics, Inc. (NASDAQ:ONCE) news were published by: Nasdaq.com which released: “Spark Therapeutics Announces New Preclinical Data for Pompe Disease Gene Therapy Candidate” on October 08, 2018, also Seekingalpha.com published article titled: “Regenxbio (Part IV): Elucidating The Prospects Of The AMD Franchise”, Seekingalpha.com published: “Sangamo (Part V): Assessing The Prospects Of SB-913” on September 11, 2018. More interesting news about Spark Therapeutics, Inc. (NASDAQ:ONCE) was released by: Seekingalpha.com and their article: “Premarket analyst action – healthcare” with publication date: October 10, 2018.

Spark Therapeutics, Inc. (NASDAQ:ONCE) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>